INVESTOR AGREEMENT By and BetweenInvestor Agreement • August 6th, 2019 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INVESTOR AGREEMENT (this “Agreement”) is made as of April 8, 2019, by and between Regeneron Pharmaceuticals, Inc. (the “Investor”), a New York corporation with its principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591, and Alnylam Pharmaceuticals, Inc. (the “Company”), a Delaware corporation with its principal place of business at 300 Third Street, Cambridge, Massachusetts 02142.
Performance Stock Unit Award Agreement Granted Under 2018 Stock Incentive PlanAlnylam Pharmaceuticals, Inc. • August 6th, 2019 • Pharmaceutical preparations • Delaware
Pursuant to the Alnylam Pharmaceuticals, Inc. 2018 Stock Incentive Plan, as amended through the date hereof (the “Plan”), Alnylam Pharmaceuticals, Inc. (the “Company”) hereby grants an award of the number of Performance Stock Units listed above (an “Award”) to the Grantee named above. Each Performance Stock Unit shall relate to one share of Common Stock, par value $0.01 per share (the “Stock”) of the Company. Unless earlier terminated, this Award shall have a term of ten (10) years from the Grant Date. For purposes of this Agreement, if the Grantee is not employed by the Company, “Employer” means the Subsidiary of the Company that employs the Grantee.
AMENDED AND RESTATED INVESTOR AGREEMENT By and Between GENZYME CORPORATION AND ALNYLAM PHARMACEUTICALS, INC. Dated as of April 8, 2019Investor Agreement • August 6th, 2019 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTOR AGREEMENT (this “Agreement”) is made as of April 8, 2019, by and between Genzyme Corporation (“Investor”), a Massachusetts corporation with its principal place of business at 500 Kendall Street, Cambridge, MA 02142, and Alnylam Pharmaceuticals, Inc. (the “Company”), a Delaware corporation with its principal place of business at 300 Third Street, Cambridge, MA 02142.
STOCK PURCHASE AGREEMENT BY AND BETWEEN REGENERON PHARMACEUTICALS, INC. AND ALNYLAM PHARMACEUTICALS, INC. DATED AS OF APRIL 8, 2019Stock Purchase Agreement • August 6th, 2019 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Confidential AMENDMENT NO. 3 TO THE COLLABORATION AGREEMENTThe Collaboration Agreement • August 6th, 2019 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 3 TO THE COLLABORATION AGREEMENT (this “Agreement”), dated as of April 8, 2019 (the “Amendment No. 3 Effective Date”), is entered into by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”), and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”).
ConfidentialGlobal License Terms • August 6th, 2019 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
THESE AMENDED AND RESTATED ALN-AT3 GLOBAL LICENSE TERMS (this “Agreement”) are entered into as of April 8, 2019 (the “A&R Execution Date”), by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”), and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”). Except where otherwise specifically provided herein, the amendments to the rights and obligations in the Original Agreement that are set forth herein shall only become binding upon the Effective Date (as defined below).
